Following the approval of therapies targeting homologous recombination defects (HRD) in several cancer settings, tumour testing for the Hereditary Breast and Ovarian Cancer Syndrome (HBOC) genes BRCA1 and BRCA2 has rapidly spread7,8. This evidence concerns the gene BRCA2 and neoplasm.